Agios Pharmaceuticals (AGIO) Announces Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16), Bloomberg Earnings reports. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The business had revenue of $9.80 million for the quarter, compared to analyst estimates of $12.65 million. During the same quarter in the prior year, the firm earned ($1.34) EPS. The firm’s quarterly revenue was down 56.7% on a year-over-year basis.

Agios Pharmaceuticals (AGIO) opened at $76.53 on Wednesday. The stock has a market capitalization of $4,285.58, a price-to-earnings ratio of -12.21 and a beta of 2.12. Agios Pharmaceuticals has a twelve month low of $45.11 and a twelve month high of $82.96.

In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 6,000 shares of Agios Pharmaceuticals stock in a transaction on Friday, December 1st. The stock was sold at an average price of $61.55, for a total transaction of $369,300.00. Following the completion of the transaction, the chief executive officer now directly owns 6,000 shares of the company’s stock, valued at $369,300. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Steven L. Hoerter sold 25,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $74.83, for a total value of $1,870,750.00. Following the completion of the transaction, the insider now directly owns 25,000 shares of the company’s stock, valued at $1,870,750. The disclosure for this sale can be found here. Over the last three months, insiders have sold 183,114 shares of company stock valued at $13,866,025. Company insiders own 5.43% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its holdings in shares of Agios Pharmaceuticals by 40.8% in the second quarter. Royal Bank of Canada now owns 9,131 shares of the biopharmaceutical company’s stock valued at $470,000 after buying an additional 2,648 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Agios Pharmaceuticals by 21.9% in the second quarter. Ameriprise Financial Inc. now owns 49,994 shares of the biopharmaceutical company’s stock valued at $2,572,000 after buying an additional 8,965 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Agios Pharmaceuticals by 31.3% in the second quarter. Northern Trust Corp now owns 232,802 shares of the biopharmaceutical company’s stock valued at $11,977,000 after buying an additional 55,560 shares during the last quarter. Alps Advisors Inc. raised its holdings in shares of Agios Pharmaceuticals by 9.1% in the third quarter. Alps Advisors Inc. now owns 47,473 shares of the biopharmaceutical company’s stock valued at $3,169,000 after buying an additional 3,962 shares during the last quarter. Finally, Brown Advisory Inc. raised its holdings in shares of Agios Pharmaceuticals by 8.5% in the third quarter. Brown Advisory Inc. now owns 291,139 shares of the biopharmaceutical company’s stock valued at $19,433,000 after buying an additional 22,736 shares during the last quarter. 82.74% of the stock is owned by institutional investors and hedge funds.

AGIO has been the topic of a number of recent research reports. Oppenheimer set a $83.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, December 26th. BidaskClub upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 15th. Finally, Royal Bank of Canada lifted their price target on shares of Agios Pharmaceuticals to $91.00 and gave the stock an “outperform” rating in a research note on Thursday, January 18th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $77.64.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/14/agios-pharmaceuticals-agio-announces-earnings-results.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply